Research in Context

Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more

A collaboration with

AENEAS2: aumolertinib–chemotherapy studied as a potential first-line option in EGFR-sensitive mutated NSCLC

Investigators reported significantly improved progression-free survival versus aumolertinib monotherapy, with no new safety signals; the authors describe the combination as a potential first-line alternative, not an established standard.

  • Ziming Li, MD; Jie Hu, MD PhD; Jianhua Chen, MD; Yan Yu, MD; Xiangjiao Meng, MD; Xiaorong Dong, MD; et al.

  • June 16, 2026

  • The Lancet Oncology
  • The Lancet Oncology, Volume 27, Issue 7, Pages 785–794
  • 10.1016/S1470-2045(26)00090-2

Share

Evidence before this study

We did a search of PubMed from Oct 18, 2001, to Oct 18, 2025, with the search terms (“non-small-cell lung cancer”) AND (“tyrosine kinase inhibitor”) AND (“epidermal growth factor receptor”) AND (“combination”) AND (“first-line”). No language restrictions were applied. The search identified two phase 3 clinical trials (the FLAURA2 [] and MARIPOSA trials []) reporting survival outcomes for third-generation epidermal growth-factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs), specifically osimertinib and lazertinib, in combination therapy for first-line treatment of metastatic NSCLC. The FLAURA2 and MARIPOSA trials showed superior progression-free survival with osimertinib-chemotherapy (hazard ratio [HR] 0·62) and the amivantamab-lazertinib combination (hazard ratio 0·70), respectively, supporting the clinical benefit of first-line combination approaches. However, the proportion of L858R mutations was relatively low in both studies (38% in FLAURA2 and 40% in MARIPOSA).

Added value of this study

The AENEAS2 study revealed that aumolertinib combined with chemotherapy significantly improved progression-free survival compared with aumolertinib monotherapy. No new safety signals have emerged with aumolertinib–chemotherapy treatment.

Implications of all the available evidence

Data from the AENEAS2 study supports use of aumolertinib in combination with chemotherapy as a potential alternative first-line treatment option for patients with EGFR-sensitive mutated NSCLC.

Source: The Lancet Oncology

Your research deserves a global audience

The Lancet Group reaches millions of clinicians and researchers worldwide.

Publish with The Lancet Group

Related Content

Vebreltinib reported to show antitumour activity in MET amplification-driven NSCLC with limited chemotherapy options

In patients ineligible for, unsuccessfully treated with, or refusing standard chemotherapy, researchers reported antitumour activity with the investigational agent vebreltinib; a phase 3 comparison with standard treatment is being initiated.

  • by Yi-Long Wu, MD; Yu Yao, MD; Jin-Ji Yang, MD; Lin Wu, PhD; Wei Zhang, PhD; Ying Wang, MD; et al.

  • December 6, 2025

Hand using a digital display with chest imaging and clinical data.
Adjuvant aumolertinib in resected EGFR-mutant NSCLC: phase 3 ARTS trial

In Chinese patients with completely resected stage II–IIIA disease, investigators reported improved disease-free survival with adjuvant aumolertinib versus placebo; overall survival was not reported.

  • by Liang Zhang, MD; Xiqin Zhang, BS; Lin Wu, MD; Wenqun Xing, BS; Chunling Liu, MS; Peng Zhang, MD; et al.

  • January 12, 2026

Clinician talking with a patient during a cancer care visit.